Drug Profile

18F FMD

Alternative Names: 18F-FMD; [18F]F-Flurimedrimer

Latest Information Update: 04 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ashvattha Therapeutics
Class Dendrimers; Diagnostic agents; Imaging agents
Mechanism of Action Diagnostic imaging enhancers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Clinical Phase Unknown Multiple sclerosis

Most Recent Events

23 Jun 2025 Clinical trials in Multiple sclerosis (IV) prior to June 2025
23 Jun 2025 Efficacy, pharmacokinetics and adverse event data from a Clinical trial in Multiple sclerosis released by Ashvattha Therapeutics
01 Jun 2025 Preclinical trials in Neurological disorders in USA (unspecified route) prior to June 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com